Treatment of Pituitary Gigantism When the Condition Remains Uncontrolled

Pituitary gigantism results from excess growth hormone secretion occurring before epiphyseal fusion. In patients where disease has not been adequately controlled, continued management requires a deliberate reassessment of the predominant clinical concern driving harm.

For uncontrolled disease, the clinical picture may be shaped primarily by tumour-related concerns, by impaired glucose metabolism, or by a combination of both. Each of these presentations carries distinct implications for how therapy should be directed.

The presence or absence of these specific concerns — tumour burden versus metabolic disturbance versus both — is central to the management decision at this stage.

Therapy is selected according to which clinical concern predominates. Different agents address different concerns, and in some situations a combination approach is indicated when more than one concern is present.

The complete structured regimen — including which specific therapies correspond to each clinical concern and how to apply them — is available in the full protocol.